9. Chou, T. C., Motzer, R. J., Tong, Y., and Bosl, G. J. Computerized
quantitation of synergism and antagonism of taxol, topotecan, and
cisplatin against human teratocarcinoma cell growth: a rational approach
to clinical protocol design [see comments]. J. Natl. Cancer Inst., 86:
1517–1524, 1994.
10. Kaufmann, S. H., Peereboom, D., Buckwalter, C. A., Svingen,
P. A., Grochow, L. B., Donehower, R. C., and Rowinsky, E. K. Cytotoxic effects of topotecan combined with various anticancer agents
inhuman cancer cell lines [see comments]. J. Natl. Cancer Inst., 88:
734 –741, 1996.
11. Janss, A. J., Craan, A., Spilsky, A., Levow, C., Yao, Y., and Phillips,
P. C. Synergistic cytotoxic effects of camptothecin and topotecan with
alkylating agents are drug-specific and dose-dependent in human brain
tumor cell lines. Proc. Am. Assoc. Cancer Res., 37: 294, 1996.
12. Waud, W. R., Rubenstein, L. V., Kalyandrug, S., Plowman, J., and
Alley, M. C. In vivo combination chemotherapy evaluations of topotecan with cisplatin and temozolomide. Proc. Am. Assoc. Cancer Res., 37:
292, 1996.
13. Houghton, J. A., Cheshire, P. J., Hallman, J. D., Lutz, L., Luo,
X., Li, Y., and Houghton, P. J. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon
adenocarcinoma and rhabdomyosarcoma. Clin. Cancer Res., 2: 107–
118, 1996.
14. Whitacre, C. M., Zborowska, E., Gordon, N. H., Mackay, W., and
Berger, N. A. Topotecan increases topoisomerase IIα levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer
Res., 57: 1425–1428, 1997.
15. Kim, R., Hirabayashi, N., Nishiyama, M., Jinushi, K., Toge, T., and
Okada, K. Experimental studies on biochemical modulation targeting
topoisomerase I and II in human tumor xenografts in nude mice. Int. J.
Cancer, 50: 760 –766, 1992.
16. Castano, I. B., Brzoska, P. M., Sadoff, B. U., Chen, H., and
Christman, M. F. Mitotic chromosome condensation in the rDNA re-quires TRF4 and DNA topoisomerase I in Saccharomyces cerevisiae.
Genes Dev., 10: 2564 –2576, 1996.
17. Houghton, J. A., Cook, R. L., Lutz, P. J., and Houghton, P. J.
Childhood rhabdomyosarcoma xenografts: response to DNA interacting
agents and agents used in current clinical therapy. Eur. J. Cancer Clin.
Oncol., 20: 955–960, 1984.
18. Houghton, J. A., Williams, L. G., Dodge, R. K., George, S. L.,
Hazelton, B. J., and Houghton, P. J. Relationship between binding
affinity, retention and sensitivity of human rhabdomyosarcoma
xenografts to Vinca alkaloids. Biochem. Pharmacol., 36: 81– 88,
1987.
19. Pratt, C. B., Stewart, C., Santana, V. M., Bowman, L., Furman, W.,
Ochs, J., Marina, N., Kuttesch, J. F., Heideman, R., Sandlund, J. T., et
al. Phase I study of topotecan for pediatric patients with malignant solid
tumors. J. Clin. Oncol., 12: 539 –543, 1994.
20. Kretchmar, C., Kletzel, M., Murray, K., Joshi, V., Smith, E., Pao,
P. V., and Castlebury, R. Upfront Phase II therapy with Taxol (Txl) and
topotecan (Topo) in untreated children (>365 days) with disseminated
(INSS stage 4) neuroblastoma (NB). A Pediatric Oncology Group
(POG) Study. Med. Pediatr. Oncol., 25: 243A, 1995.
21. Vietti, T., Crist, W., Ruby, E., Raney, B., Ruyman, F., Link, M.,
Grier, H., and Maurer, H. Topotecan window in patients with rhabdomyosarcoma (RMS): an IRSG study. Proc. Am. Assoc. Clin. Oncol.,
16: 510A, abstract #1837, 1997.
22. Zamboni, W. C., Stewart, C. F., Thompson, J., Santana, V., Cheshire, P. J., Richmond, L. B., Liu, X., Houghton, J. A., and Houghton, P. J.
The Relationship between topotecan systemic exposure and tumor re-sponse in human neuroblastoma xenografts. J. Natl. Cancer Inst., 90:
505–511, 1998.
23. Thompson, J., Zamboni, W. C., Cheshire, P. J., Lutz, L., Luo, X.,
Li, Y., Houghton, J. A., Stewart, C. F., and Houghton, P. J. Efficacy of
systemic administration of irinotecan against neuroblastoma xenografts.
Clin. Cancer Res., 3: 423– 431, 1997.
24. Houghton, J. A., Houghton, P. J., Hazelton, B. J., and Douglass,
E. C. In situ selection of a human rhabdomyosarcoma resistant to
